Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Drug Factories

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Aug 23, 2022 10:59am

205 Views

Post# 34914118

RE:Drug Factories

Capitalista wrote: This is interesting. The method of application (invasive or at least keyhole surgery is required) is much more difficult than Pela's intravenous treatment though. Even if approved, they are not working in ONC's sweet spots (mBC and pancreatic cancer).

https://newatlas.com/medical/implantable-drug-factory-beads-mesothelioma-tumors-mice-days/

Added today. This story is about to give a good return to the long holders. My own impression of course. GL

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?